Physician profile
Casey Jamison
NPI 1043614233
$2,271.39
in general payments reported to CMS, 2019-2025
14 companies · $594 in 2025
The $594 reported for 2025 was more than what 89% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $481 · 2023: $401 · 2024: $552 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.51 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.66 | 2021-2025 | |
| Novo Nordisk INC | $431.26 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $230.26 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $156.98 | 2023-2025 | |
| Astellas Pharma US INC | $141.87 | 2023-2025 | Veozah |
| Acella Pharmaceuticals, LLC | $60.86 | 2022-2024 | NP Thyroid 60 |
| Biohaven Pharmaceutical Holding Company LTD. | $32.89 | 2022 | |
| Axsome Therapeutics, INC. | $30.93 | 2025 | Symbravo |
| Corcept Therapeutics | $26.73 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $21.48 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $18.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.82 | 2021 | |
| Exeltis, USA INC. | $14.08 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Jamison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.